Nalidixic acid

Nalidixic acid

Systematic (IUPAC) name
1-Ethyl-7-methyl-4-oxo-[1,8]naphthyridine-3-carboxylic acid
Clinical data
AHFS/Drugs.com	Consumer Drug Information
Pregnancy category	B U.S.
Legal status	Not FDA approved
Routes of administration	Oral
Pharmacokinetic data
Protein binding	90%
Metabolism	Partially Hepatic
Biological half-life	6-7 hours, significantly longer in renal impairment
Identifiers
CAS Number	389-08-2 Y
ATC code	J01MB02 (WHO)
PubChem	CID: 4421
DrugBank	DB00779 Y
ChemSpider	4268 Y
UNII	3B91HWA56M Y
KEGG	D00183 Y
ChEBI	CHEBI:100147 Y
ChEMBL	CHEMBL5 Y
Chemical data
Formula	C12H12N2O3
Molecular mass	232.235 g/mol
SMILES O=C\2c1c(nc(cc1)C)N(/C=C/2C(=O)O)CC
InChI InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17) Y Key:MHWLWQUZZRMNGJ-UHFFFAOYSA-N Y
(verify)

Nalidixic acid (tradenames Nevigramon, Neggram, Wintomylon and WIN 18,320) is the first of the synthetic quinolone antibiotics.

In a technical sense, it is a naphthyridone, not a quinolone: its ring structure is a 1,8-naphthyridine nucleus that contains two nitrogen atoms, unlike quinoline, which has a single nitrogen atom.

Synthetic quinolone antibiotics were discovered by George Lesher and coworkers as a byproduct of chloroquine manufacture in the 1960s. Used clinically from 1967.

Nalidixic acid is effective primarily against gram-negative bacteria, with minor anti-gram-positive activity. In lower concentrations, it acts in a bacteriostatic manner; that is, it inhibits growth and reproduction. In higher concentrations, it is bactericidal, meaning that it kills bacteria instead of merely inhibiting their growth.

It has historically been used for treating urinary tract infections, caused, for example, by Escherichia coli, Proteus, Shigella, Enterobacter, and Klebsiella. It is no longer clinically used for this indication in the USA as less toxic and more effective agents are available.

It is also a tool in studies as a regulation of bacterial division. It selectively and reversibly blocks DNA replication in susceptible bacteria. Nalidixic acid and related antibiotics inhibit a subunit of DNA gyrase and topoisomerase IV and induce formation of cleavage complexes. It also inhibits the nicking-closing activity on the subunit of DNA gyrase that releases the positive binding stress on the supercoiled DNA.

Adverse effects

Hives, rash, intense itching, or fainting soon after a dose may be a sign of anaphylaxis. Common adverse effects include rash, itchy skin, blurred or double vision, halos around lights, changes in color vision, nausea, vomiting, and diarrhea. Nalidixic acid may also cause convulsions and hyperglycaemia, photosensitivity reactions, and sometimes haemolytic anaemia, thrombocytopenia or leukopenia. Particularly in infants and young children, has been reported occasionally increased intracranial pressure.

Overdose

In case of overdose the patient experiences headache, visual disturbances, balance disorders, mental confusion, metabolic acidosis and seizures.

Spectrum of bacterial susceptibility and resistance

Aeromonas hydrophila, Clostridium and Haemophilus are generally susceptible to nalidixic acid, while other bacteria such as Bifidobacteria, Lactobacillus, Pseudomonas and Staphylococcus are resistant.

Synthesis

EMME (Ethoxy Methylene Malonic Diethyl Ester)

Naldixic acid synthesis:

See also

• Amfonelic acid
• Oxolinic acid

External links

• MedlinePlus DrugInfo medmaster-a682042